ASH News Daily 2017 - Issue 3 - B-16

ASH News Daily

Page B-16

Monday, December 11, 2017

career-enhancemenT awardS

Supporting the Future of Hematology Through
the ASH Scholar Award Program

he ASH Scholar Award program is the longest standing
award program at ASH and
one of the most highly regarded.

For almost three decades, ASH has
supported hundreds of fellows and
junior faculty in both basic and
clinical/translational research by

providing partial salary or other
support during the critical period
between completion of training and
the establishment of one's inde-

INTRODUCING

pendent career. The awards, in the
amount of $100,000 for fellows and
$150,000 for junior faculty over a
two- to three-year period, are made
possible through grants from the
corporate community, individual
donors, foundations, and funds committed by the Society. To learn more
about the ASH Scholar Award program, please visit www.hematology.
org/awards.

BASIC/TRANSLATIONAL
RESEARCH JUNIOR FACULTY

A new way of experiencing
patient support
Pfizer Oncology Together combines the support healthcare
professionals expect for their patients with the support their
patients deserve. We're committed to helping your patients
get their prescribed treatment as well as services that are
tailored to their needs. All in one place.

(Monday-Friday 8 AM -8 PM ET)

PfizerOncologyTogether.com

We're here to help your patients with*:
* Locating rides and lodging

* Access and reimbursement

* Connections to outreach programs

* Patient financial assistance

* Workplace transitions

* And much more

for appointments

1-877-744-5675

support

Visit us at:

BOOTH 2233

* Some services are provided through independent third-party patient
advocacy organizations.

†

‡

gemtuzumab ozogamicin INJECTION
FOR IV INFUSION
4.5 mg single-dose vial

Please see full Prescribing Information, Important Safety Information, and Indication(s) for IBRANCE® (palbociclib) at IBRANCEhcp.com,
TORISEL® (temsirolimus) at TORISELhcp.com, INLYTA® (axitinib) at INLYTAhcp.com, XALKORI® (crizotinib) at XALKORIhcp.com,
and BOSULIF® (bosutinib) at BOSULIFhcp.com.
†

Please see full Prescribing Information, including BOXED WARNING for hepatotoxicity, Important Safety Information, and Indications for
SUTENT® (sunitinib malate) at SUTENThcp.com. Hepatotoxicity may be severe, and deaths have been reported.

‡

Please see full Prescribing Information, including BOXED WARNING for hepatotoxicity, including VOD, and increased risk of post-HSCT
non-relapse mortality; Important Safety Information; and Indication for BESPONSA™ (inotuzumab ozogamicin) at BESPONSAhcp.com.

Please see full Prescribing Information, including BOXED WARNING for hepatotoxicity, Important Safety Information, and Indications for
MYLOTARG™ (gemtuzumab ozogamicin) at MYLOTARGhcp.com.
Prescribing Information for all products is also available at the Pfizer booth exhibit.

PP-ONC-USA-0600-02

September 2017

Margarida Almeida
Santos, PhD, MS
Dr. Santos joined MD Anderson Cancer Center as an assistant
professor in June 2015. Dr. Santos'
research into the
functions of an
epigenetic
factor, MLL4, during normal blood
development
and
leukemias
has
completely
changed
thinking in the field regarding connections between DNA
damage and cancer. Rather than
promoting mutations that drive
cancer formation, Dr. Santos found
that DNA damage can drive cellular differentiation, thereby limiting leukemia development. This
work provides profound insights
into leukemogenesis as well as new
therapeutic options for these and
other cancers. Dr. Santos did her
graduate studies at Lisbon Medical School and came to the United
States as a visiting fellow at the
University of Pennsylvania in the
laboratory of Dr. Warren Pear. She
decided to further her training as
a postdoctoral fellow with Dr. Andre Nussenweig at the National
Institutes of Health. Initially, Dr.
Santos focused on chromatin modifications in the DNA damage response during B cell class switch
recombination and later carried
out a landmark study focused on
the functions of MLL4 in AML. Dr.
Santos and her team are passionate
and committed to studying blood
cancers with the goal of developing new therapies for these deadly
diseases. The ASH Scholar Award
»» ASH SCHOLARS Page B-22

http://www.hematology.org/awards http://www.hematology.org/awards

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 3